Clinical Trials
10 trialsNCT06760819 2026-06-04
panSOHO
Bayer
Phase 2 Recruiting
NCT07334119 2026-05-20
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Phase 1 Recruiting
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT03797326 2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02576431 2026-04-28
NAVIGATE
Bayer
Phase 2 Completed
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT07319767 2026-04-06
Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors
Shanghai Zhongshan Hospital
Completed
NCT06451497 2026-04-02
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Phase 1 Recruiting
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT06293898 2026-03-23
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune Inc.
Phase 1 Recruiting